Hepatic over-expression of peroxisome proliferator activated receptor gamma2 in the ob/ob mouse model of non-insulin dependent diabetes mellitus - PubMed (original) (raw)

Hepatic over-expression of peroxisome proliferator activated receptor gamma2 in the ob/ob mouse model of non-insulin dependent diabetes mellitus

R Rahimian et al. Mol Cell Biochem. 2001 Aug.

Abstract

Studies of the molecular basis of insulin resistance have focused on the peroxisome proliferator activated receptor gamma (PPARgamma, gamma1 and gamma2). The aim of this study was to determine whether the insulin resistance in liver of diabetic animals is associated with abnormal expression of these receptors. PPARgamma mRNA and protein expression levels were quantified in liver of 9-week-old male ob/ob mice as a model of diabetes and compared to age- and gender-matched wild type control animals of the same genetic background. Semi-quantitative reverse transcription-polymerase chain reaction, using 18S rRNA as an internal standard, indicated that PPARgamma2 mRNA was significantly upregulated in ob/ob liver vs. that in wild type mice. Western blotting revealed greater immunoreactivity of PPARgamma2 in liver from ob/ob mice relative to that in wild type mice. An index of insulin resistance (product of serum glucose and insulin concentration) was correlated with liver PPARgamma2 mRNA expression (r = 0.776; p < 0.001). The findings that liver PPARgamma2 expression is (1) significantly elevated in the ob/ob model of diabetes and (2) positively associated with an index of insulin resistance, suggests a possible compensatory response through which type II diabetic and obese organisms strive to maintain insulin sensitivity of the liver.

PubMed Disclaimer

Cited by

CCAAT/enhancer-binding protein beta deletion reduces adiposity, hepatic steatosis, and diabetes in Lepr(db/db) mice.
Schroeder-Gloeckler JM, Rahman SM, Janssen RC, Qiao L, Shao J, Roper M, Fischer SJ, Lowe E, Orlicky DJ, McManaman JL, Palmer C, Gitomer WL, Huang W, O'Doherty RM, Becker TC, Klemm DJ, Jensen DR, Pulawa LK, Eckel RH, Friedman JE. Schroeder-Gloeckler JM, et al. J Biol Chem. 2007 May 25;282(21):15717-29. doi: 10.1074/jbc.M701329200. Epub 2007 Mar 26. J Biol Chem. 2007. PMID: 17387171 Free PMC article.
Histone H3K9 demethylase JMJD2B induces hepatic steatosis through upregulation of PPARγ2.
Kim JH, Jung DY, Nagappan A, Jung MH. Kim JH, et al. Sci Rep. 2018 Sep 13;8(1):13734. doi: 10.1038/s41598-018-31953-x. Sci Rep. 2018. PMID: 30214048 Free PMC article.
Effect of Chronic Pioglitazone Treatment on Hepatic Gene Expression Profile in Obese C57BL/6J Mice.
Jia C, Huan Y, Liu S, Hou S, Sun S, Li C, Liu Q, Jiang Q, Wang Y, Shen Z. Jia C, et al. Int J Mol Sci. 2015 May 29;16(6):12213-29. doi: 10.3390/ijms160612213. Int J Mol Sci. 2015. PMID: 26035752 Free PMC article.
Tetrahydroxanthohumol, a xanthohumol derivative, attenuates high-fat diet-induced hepatic steatosis by antagonizing PPARγ.
Zhang Y, Bobe G, Miranda CL, Lowry MB, Hsu VL, Lohr CV, Wong CP, Jump DB, Robinson MM, Sharpton TJ, Maier CS, Stevens JF, Gombart AF. Zhang Y, et al. Elife. 2021 Jun 15;10:e66398. doi: 10.7554/eLife.66398. Elife. 2021. PMID: 34128467 Free PMC article.
Endocannabinoid System in Hepatic Glucose Metabolism, Fatty Liver Disease, and Cirrhosis.
Bazwinsky-Wutschke I, Zipprich A, Dehghani F. Bazwinsky-Wutschke I, et al. Int J Mol Sci. 2019 May 22;20(10):2516. doi: 10.3390/ijms20102516. Int J Mol Sci. 2019. PMID: 31121839 Free PMC article. Review.

References

1. Diabetes. 1999 Apr;48(4):699-705 - PubMed
1. Lancet. 1995 Jul 8;346(8967):120-1 - PubMed
1. Nature. 1997 Mar 27;386(6623):407-10 - PubMed
1. J Clin Endocrinol Metab. 1998 Aug;83(8):2830-5 - PubMed
1. Metabolism. 1993 Oct;42(10):1365-9 - PubMed

Hepatic over-expression of peroxisome proliferator activated receptor gamma2 in the ob/ob mouse model of non-insulin dependent diabetes mellitus - PubMed (original) (raw)